G&E Herbal Biotechnology Co (ROCO:4911) Altman Z2-Score: 25.10 (As of Jul. 21, 2026) — 13% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4911 G&E Herbal Biotechnology Co Ltd ROCO:4911
63 GF Score
Price NT$34.80
GF Value NT$87.01
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is G&E Herbal Biotechnology Co Altman Z2-Score?

G&E Herbal Biotechnology Co ROCO:4911 -0.14% 63 Altman Z2-Score is 25.10 as of Jul. 21, 2026, which is 13% below its 10-year median of 28.97. GuruFocus rates ROCO:4911 with a GF Score™ of 63/100 and a GF Value™ of NT$87.01 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,390 Biotechnology companies, G&E Herbal Biotechnology Co ranks better than 95.04% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

G&E Herbal Biotechnology Co has a Altman Z2-Score of 25.10, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for G&E Herbal Biotechnology Co's Altman Z2-Score or its related term are showing as below:

ROCO:4911' s Altman Z2-Score Range Over the Past 10 Years
Min: 8.55   Med: 28.97   Max: 88.6
Current: 25.1

During the past 13 years, G&E Herbal Biotechnology Co's highest Altman Z2-Score was 88.60. The lowest was 8.55. And the median was 28.97.


G&E Herbal Biotechnology Co  (ROCO:4911) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


G&E Herbal Biotechnology Co Altman Z2-Score Related Terms


G&E Herbal Biotechnology Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for G&E Herbal Biotechnology Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

G&E Herbal Biotechnology Co Altman Z2-Score Chart

G&E Herbal Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.02 8.55 9.38 10.42 25.10

G&E Herbal Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.42 10.36 9.79 18.44 25.10

ROCO:4911 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, G&E Herbal Biotechnology Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


G&E Herbal Biotechnology Co Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G&E Herbal Biotechnology Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where G&E Herbal Biotechnology Co's Altman Z2-Score falls into.


ROCO:4911
63GF Score
G&E Herbal Biotechnology Co Ltd ROCO:4911
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

G&E Herbal Biotechnology Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

G&E Herbal Biotechnology Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.4385+3.26*0.1427+6.72*0.1624+1.05*19.6851
=25.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was NT$975.2 Mil.
Total Current Assets was NT$474.7 Mil.
Total Current Liabilities was NT$47.1 Mil.
Retained Earnings was NT$139.2 Mil.
Pre-Tax Income was 31.059 + 41.005 + 44.895 + 41.434 = NT$158.4 Mil.
Interest Expense was -0.005 + -0.007 + -0.008 + -0.009 = NT$-0.0 Mil.
Total Liabilities was NT$47.1 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(474.69 - 47.053)/975.22
=0.4385

X2=Retained Earnings/Total Assets
=139.197/975.22
=0.1427

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(158.393 - -0.029)/975.22
=0.1624

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(928.074 - 0)/47.146
=19.6851

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

G&E Herbal Biotechnology Co has a Altman Z2-Score of 25.10 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 25.10 mean?
G&E Herbal Biotechnology Co (ROCO:4911) has a Altman Z2-Score of 25.10 as of Jul. 21, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on G&E Herbal Biotechnology Co and its competitors. This is 13% below median its historical median of 28.97. Over the past decade, G&E Herbal Biotechnology Co's Altman Z2-Score has ranged from 8.55 to 88.60. According to the industry distribution chart, G&E Herbal Biotechnology Co ranks #69 out of 1390 companies in the Biotechnology industry, placing it in the top 5%.
Is G&E Herbal Biotechnology Co's Altman Z2-Score too high?
G&E Herbal Biotechnology Co's current Altman Z2-Score of 25.10 is 13% below median its 10-year median of 28.97. Over the past 10 years, this metric has ranged from a low of 8.55 to a high of 88.60. Based on the distribution chart, G&E Herbal Biotechnology Co ranks #69 out of 1390 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, G&E Herbal Biotechnology Co has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does G&E Herbal Biotechnology Co's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, G&E Herbal Biotechnology Co ranks #69 out of 1390 companies for Altman Z2-Score. This places G&E Herbal Biotechnology Co in the top 5% of its industry — outperforming the majority of peers. Historically, G&E Herbal Biotechnology Co's own Altman Z2-Score has ranged from 8.55 to 88.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on G&E Herbal Biotechnology Co and its competitors. G&E Herbal Biotechnology Co's current Altman Z2-Score is 25.10, which is 13% below median its own 10-year median of 28.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is G&E Herbal Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, G&E Herbal Biotechnology Co (ROCO:4911) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$87.01, compared to a current price of NT$34.80 — trading 60% below its estimated fair value. The current Altman Z2-Score is 25.10, which is 13% below median its 10-year median of 28.97. G&E Herbal Biotechnology Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For G&E Herbal Biotechnology Co (ROCO:4911), the current Altman Z2-Score is 25.10 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is G&E Herbal Biotechnology Co (ROCO:4911) Overvalued in 2026?

Based on GuruFocus' analysis, G&E Herbal Biotechnology Co stock appears to be undervalued. The current stock price of NT$34.80 is trading 60% below its estimated GF Value™ of NT$87.01. GuruFocus considers G&E Herbal Biotechnology Co to be Significantly Undervalued.

Key valuation signals for ROCO:4911:

  • Altman Z2-Score: 25.10 (13% below median its 10-year median of 28.97)
  • GF Value™: NT$87.01 vs. price of NT$34.80 (60% below fair value)
  • GF Score™: 63/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


G&E Herbal Biotechnology Co Business Description

Address No. 92, Keji 5th Road, Annan District, Tainan, TWN, 709015
G&E Herbal Biotechnology Co Ltd is a Taiwan-based biopharmaceutical company. It specializes in the production of Western conventional drugs, Chinese traditional drugs, unclassified food, cosmetics, and health products. The company is focused on botanical extraction technology and products. Its products include botanical extract toner, total moisture conditioning cream, whitening clear cream, and firming essence cream.
63GF Score

Get the complete analysis for ROCO:4911

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.80
Price
NT$87.01
GF Value